ImmunityBio, Inc.（股票代码：IBRX）在周二夜盘交易中大跌5.51%，主要原因是该公司发布的季度业绩未能达到分析师预期。
根据ImmunityBio公布的财报，截至2025年3月31日的季度调整后每股亏损为15美分，高于分析师平均预期的13美分亏损。这一数字虽然较去年同期的每股亏损20美分有所改善，但仍未能满足市场预期。公司当季净亏损达1.2965亿美元，这一巨额亏损可能引发了投资者对公司财务状况的担忧。
尽管如此，ImmunityBio的季度营收表现亮眼，同比增长41192.5%，达到1652万美元，超过分析师预期的1602万美元。然而，这一显著的收入增长似乎未能抵消盈利未达预期带来的负面影响。值得注意的是，尽管公司业绩存在不足，分析师对该股票的平均评级仍维持在"买入"，12个月目标价中位数为8.00美元。这表明分析师仍对公司的长期发展前景保持乐观态度，但短期内股价可能会因业绩不佳而承压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.